Clinical Trial Update: A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ramucirumab (IMC-12/IMC-A12) plus mitoxantrone and prednisone in prostate cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Deltasone (prednisone)
• Novantrone (mitoxantrone)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-06-18